Warring Shelby R, Biggs Jessica M, Morgan Jill A, Parbuoni Kristine A
Department of Pharmacy (SRW, JMB), University of Maryland Medical Center, Baltimore, MD.
Department of Practice, Sciences, and Health Outcomes Research (JAM, KAP), University of Maryland School of Pharmacy, Baltimore, MD.
J Pediatr Pharmacol Ther. 2024 Dec;29(6):645-649. doi: 10.5863/1551-6776-29.6.645. Epub 2024 Dec 9.
Data comparing the safety profiles of nafcillin and oxacillin are limited in the pediatric patient setting. This study was conducted to compare adverse effect profiles of nafcillin and oxacillin.
This was a single center retrospective study including patients admitted to a children's hospital who received either nafcillin or oxacillin. Patients were excluded if they were older than 18 years or if therapy duration was less than 48 hours. The primary objective was to compare the cumulative sum of adverse effects of nafcillin to oxacillin, including incidence of hypokalemia, nephrotoxicity, hepatotoxicity, neutropenia, infusion-related reactions, loss of intravenous access, and early discontinuation of therapy. Secondary endpoints included comparison of the incidence of each adverse effect collected.
Fifty-three patient encounters (representing 46 patients) were included, with 17 patients receiving nafcillin and 36 patients receiving oxacillin. There was no difference between the cumulative sum of adverse effects for nafcillin (n = 16) and oxacillin (n = 45), p = 1. Acute kidney injury (AKI) occurred with both nafcillin and oxacillin at similar rates (21% vs 30%; p = 0.72), as well as hypokalemia for both nafcillin and oxacillin (50% vs 43%; p = 0.46). All but 1 patient who experienced AKI were receiving other nephrotoxin(s) during therapy. Changes in liver transaminases were not significant for either drug. A significant decline in median absolute neutrophil count was noted from pre to post treatment with oxacillin (8400 to 6000 cells/µL; p = 0.002).
Our study found no significant difference in adverse effects of nafcillin and oxacillin. Both treatment groups experienced AKI and hypokalemia. Larger studies are needed to determine if one drug is safer than the other.
在儿科患者中,比较萘夫西林和苯唑西林安全性的相关数据有限。本研究旨在比较萘夫西林和苯唑西林的不良反应情况。
这是一项单中心回顾性研究,纳入了一家儿童医院中接受萘夫西林或苯唑西林治疗的患者。如果患者年龄超过18岁或治疗时间少于48小时,则将其排除。主要目的是比较萘夫西林与苯唑西林的不良反应累积总和,包括低钾血症、肾毒性、肝毒性、中性粒细胞减少、输液相关反应、静脉通路丧失以及治疗提前终止的发生率。次要终点包括对所收集的每种不良反应发生率的比较。
纳入了53例患者就诊情况(代表46例患者),其中17例患者接受萘夫西林治疗,36例患者接受苯唑西林治疗。萘夫西林(n = 16)和苯唑西林(n = 45)的不良反应累积总和无差异,p = 1。萘夫西林和苯唑西林发生急性肾损伤(AKI) 的发生率相似(21% 对30%;p = 0.72),低钾血症的发生率也相似(50% 对43%;p = 0.46)。除1例发生AKI的患者外,所有患者在治疗期间均接受了其他肾毒性药物。两种药物的肝转氨酶变化均无显著意义。苯唑西林治疗前后,中性粒细胞绝对计数中位数显著下降(从8400降至6000个细胞/µL;p = 0.002)。
我们的研究发现萘夫西林和苯唑西林的不良反应无显著差异。两个治疗组均出现了AKI和低钾血症。需要进行更大规模的研究来确定一种药物是否比另一种药物更安全。